BTHIinactive

NANOMIX CORP

Healthcare·Neurology·Commercial

NeurologyInfectious DiseaseMetabolicNephrology

NANOMIX CORP (BTHI): 6 pipeline candidates. Updated within the last hour.

9.9/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

D/E -1.02 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth9.8

6 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for NANOMIX CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$17K

Quarterly Burn

—

Runway

—

Revenue

—

Pipeline (6 candidates)

Drug	Phase	Indication
bti-320	Phase 2	Type 2 diabetes and partial weight management
bti-410	Phase 2	Type 2 diabetes and Type 1 diabetes (post-kidney transplant)
covid-19 rapid antigen panel	Preclinical	Qualitative detection of nucleocapsid antigens from SARS-CoV...
ipoxyn	Preclinical	Prevention of necrosis and treatment for ischemia (e.g., dia...
risperidone	Approved	1 INDICATIONS AND USAGE Risperidone for extended-release inj...
s1 panel assay	Approved	Critical infections including sepsis

·1 FDA decision

Frequently asked questions

How many drug candidates are in NANOMIX CORP's pipeline?

NANOMIX CORP (BTHI) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is NANOMIX CORP's lead drug candidate?

NANOMIX CORP's most advanced tracked candidate is bti-320 (Phase 2) for Type 2 diabetes and partial weight management.

Get the full picture on NANOMIX CORP

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free Analysis Browse Calendar